You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
At the ASHG 2020 virtual meeting, researchers presented data showing they could use the method to enrich for placental DNA in maternal plasma samples.
The company, which originally announced plans for a possible spin off in June, will hold a shareholder meeting to vote on the details in October.
The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.
The new company, called Infinity Biologix, will continue to operate out of Rutgers' New Brunswick campus with over 400 technicians and scientists.
The Harvard spinout wants its instrumentation and reagent packages to ease the transition for labs interested in high-resolution imaging studies.
Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.
The firm presented a poster at ASCO suggesting that its StemPrintER platform outperforms Exact Science's Oncotype Dx for predicting breast cancer recurrence.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.
The company, which spun out of the Netherlands Cancer Institute, has developed technology to identify promoters and enhancers.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.